Dr. André Choulika is Chairman of the Board of Directors and Chief Executive Officer of Cellectis. He is one of the founders of Cellectis and served as Chief Executive Officer since the Company's inception in 1999. He has been Chairman of the Board of Directors since 2011 and President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. 

André Choulika
Chairman of the Board and CEO
The Cellectis Group

If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.